Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Viking Therapeutics
Biotech
Viking to charge quickly into phase 3 with obesity med
Viking will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.
Annalee Armstrong
Jul 25, 2024 9:19am
Pfizer's obesity pill news leaves analysts wanting
Jul 12, 2024 10:17am
Terns' ex-MASH drug cuts fat, not muscle in GLP-1 combo in mice
Jun 25, 2024 8:51am
Viking's MASH drug scores where Madrigal's didn't
Jun 4, 2024 1:51pm
Viking sails oral weight loss drug to ph 2 after clinical win
Mar 26, 2024 10:04am
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Mar 15, 2024 10:55am